Congress mandates pharmacy access to birth control, bans refusals based on belief

What it does

This bill requires pharmacies that stock contraception to dispense FDA-approved birth control and related medications without delay when requested, or to refer customers to another pharmacy or expedite ordering if out of stock. Pharmacies must maintain a non-hostile environment, prevent employee interference, and cannot misrepresent availability or breach confidentiality. Violations trigger civil penalties up to $1,000/day (capped at $100,000 per case) and private lawsuits for damages. The bill carves out refusals based on lack of valid prescription, inability to pay, or genuine clinical judgment—but explicitly bars Religious Freedom Restoration Act defenses.

Why we flagged it

The bill's core mechanism is a direct operational duty imposed on pharmacies—stock and dispense contraception without delay or facilitate access—backed by civil penalties and private litigation. This is a public-health access mandate, not a subsidy, tax provision, or commemorative measure.

What the text implies

• The bill's private cause of action (allowing customers to sue for damages) may generate significant litigation against pharmacy chains and independent pharmacies, potentially raising compliance costs and insurance premiums that could be passed to consumers.
• The 'without delay' standard is tied to 'usual and customary timeframe' for other products, creating ambiguity in enforcement—pharmacies may argue that contraception ordering timelines match other specialty medications, potentially leading to disputes.
• The carve-out for 'professional clinical judgment' is undefined beyond 'prevailing medical standards,' leaving room for pharmacists to claim judgment-based refusals that may be difficult to distinguish from conscience-based refusals in litigation.
• The bill does not address inventory stocking requirements, so pharmacies can minimize contraception stock and rely on referrals/ordering, effectively shifting burden to customers while technically complying.
• Interaction with state conscience laws: the bill bars RFRA defenses federally but does not preempt state-level religious exemptions, creating a patchwork where some states may still permit refusals under state law.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens gain enforceable access to FDA-approved contraception without pharmacist obstruction, addressing documented barriers rooted in discrimination and personal belief. The bill removes a concrete harm (denial of legal medication) and creates a private right of action for aggrieved individuals, strengthening accountability. Carve-outs for clinical judgment and payment inability are narrow and standard.

Who stands to gain

• Pharmaceutical manufacturers (increased contraceptive sales volume and consistency)
• Pharmacy chains (regulatory compliance costs offset by increased customer traffic and contraceptive
• Legal services (private litigation and enforcement defense)

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), State pharmacy boards, Pharmacy chains and independent pharmacies, Pharmaceutical manufacturers (BMY, GH, PFE, JNJ), DVA (DaVita, dialysis/healthcare services), RFRA (Religious Freedom Restoration Act of 1993), Title VII (Civil Rights Act of 1964), ACA (Patient Protection and Affordable Care Act)

Where it stands

25 cosponsors: 25 Democrats.

• Jul 16, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Jul 16, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $43,451 in lobbying spend. A filing names 48 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Cory Booker, the sponsor, reported $496,300 in PAC receipts in the 2026 cycle.

• Power to Decide — $33,451 on 2 filings
• National Council of Jewish Women — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.